I

Immunomedics

104 employees

Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.

Investor insights

Funding rounds participated in

$250M sweet spot round size

Investor type

Public Company

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

1982

Funding rounds raised

Total raised

$250M

from investors over 1 rounds

I

Immunomedics raised $250M on January 4, 2020